119 related articles for article (PubMed ID: 2230348)
1. Clinical evaluation of CA 15.3 in the post-operative follow-up of breast cancer patients.
Scaramuzzi M; Amorotti C; De Palma M; Falchi AM; Baldini E; De Maria D; Casolo P
Int J Biol Markers; 1990; 5(1):22-6. PubMed ID: 2230348
[TBL] [Abstract][Full Text] [Related]
2. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CA 15.3 in metastatic breast cancer.
Scaramuzzi M; Amorotti C; De Palma M; Falchi AM; De Maria D; Casolo P
Int J Biol Markers; 1990; 5(1):35-7. PubMed ID: 2230350
[TBL] [Abstract][Full Text] [Related]
5. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
6. Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer.
Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Foudeh MO; Awwad AH; Nasralla MY; Szymendera JJ
Int J Biol Markers; 1989; 4(2):81-6. PubMed ID: 2768892
[TBL] [Abstract][Full Text] [Related]
7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
8. Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
Eur J Cancer; 1992; 28A(4-5):845-50. PubMed ID: 1524905
[TBL] [Abstract][Full Text] [Related]
9. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.
Colomer R; Ruibal A; Genollá J; Rubio D; Del Campo JM; Bodi R; Salvador L
Breast Cancer Res Treat; 1989 Mar; 13(2):123-33. PubMed ID: 2730960
[TBL] [Abstract][Full Text] [Related]
10. An assessment of the clinical usefulness of two serum markers, CA15 3 and HMFG 2 in localized and metastatic breast cancer.
Bliss P; Fisken J; Roulsten J; Leonard RC
Dis Markers; 1993 Jun; 11(1):45-8. PubMed ID: 8358965
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer and clinical utility of CA 15-3 and CEA.
Jäger W; Krämer S; Palapelas V; Norbert L
Scand J Clin Lab Invest Suppl; 1995; 221():87-92. PubMed ID: 7652494
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
13. [CA 15.3 and early diagnosis of recurrence in breast cancer].
Basuyau JP; Brunelle P; Charrot P; Chevallier B; Delapierre F; Graic Y; Julien JP; Veyret C
Bull Cancer; 1993 Mar; 80(3):213-8. PubMed ID: 8173173
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast.
Omar YT; Behbehani AE; al-Naqeeb N; Motawy MM; Folldi MO; Awwad AH; Nasralla MY; Szymendera JJ
Int J Biol Markers; 1988; 3(3):165-71. PubMed ID: 3230336
[TBL] [Abstract][Full Text] [Related]
15. CA-549 serum levels in breast cancer monitoring.
Zamagni C; Martoni A; Cacciari N; Bellanova B; Vecchi F; Pannuti F
Int J Biol Markers; 1992; 7(4):217-21. PubMed ID: 1491176
[TBL] [Abstract][Full Text] [Related]
16. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
Fritsche E; Benz J
Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
[TBL] [Abstract][Full Text] [Related]
17. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.
Martoni A; Zamagni C; Bellanova B; Zanichelli L; Vecchi F; Cacciari N; Strocchi E; Pannuti F
Eur J Cancer; 1995 Sep; 31A(10):1615-21. PubMed ID: 7488411
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
19. The relation between tumor marker Ca 15-3 and metastases in interpectoral lymph nodes in breast cancer patients.
Vrdoljak DV; Knezevic F; Ramljak V
Saudi Med J; 2006 Apr; 27(4):460-2. PubMed ID: 16598320
[TBL] [Abstract][Full Text] [Related]
20. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
